Study Evaluating Sirolimus in Kidney Transplant Recipients.

Inclusion Criteria: * Age is older than 18 years. * End-stage renal disease, with subjects scheduled for kidney transplant. * Women of childbearing potential must not be pregnant and agree to medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of assigned treatment. Other inclusion applies. Exclusion Criteria: * Evidence of active systemic or localized major infection. * Use of any investigational drug or treatment up to 4 weeks prior to study entry. * Known hypersensitivity to SRL or its derivatives, macrolide antibiotics, corticosteroids, basiliximab. * Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant). * Immunosuppression therapies other than those allowed in the protocol. * Treatment with voriconazole, terfenadine, cisapride, astemizole, pimozide, or ketoconazole (all known to interact with SRL) that is not discontinued prior to study entry. Other exclusion applies.